Long-term safety study of HSK39297 for IgA kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous HSK39297-202 study and your doctor thinks the medicine is working well for you
- Your kidney function score (eGFR) must be at least 30 mL/min/1.73 m² (a measure of how well your kidneys are filtering waste)
- You must stay on stable doses of kidney-protective medications like ACE inhibitors, ARBs, SGLT2 inhibitors, or other prescribed treatments
- You must have had vaccines against meningitis and pneumococcal disease, with booster shots if needed
- Women of childbearing age must use highly effective birth control; men must use highly effective birth control for 90 days after stopping the medicine
- You must be willing to follow all study visits and procedures and sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
This study tests a new medicine called FXS6837 for people with IgA nephropathy, a kidney disease. It is a long-term follow-up for people who already finished a previous study with this medicine, to see if it keeps working safely over time.
This trial tests a new medicine called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and helps reduce protein in the urine, which is a sign of kidney damage.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.